Introduction: Cisplatin (CIS) is averse -neoplastic substitute pro the therapy of solid tumors. Conversely, an extraordinary
incidence of harsh ototoxicity is prevalant in patients remedied by CIS. Dexamethasone (DX) is a synthetic steroid equivalent
expended for the treatment of distinctive inner ear diseases. Erythropoietin (ER) had well-established erythropoietic function
plus strong anti-inflammatory, anti-apoptotic validity.
Purpose: The principle of this study was to assess the otoprotective effects of dexamethasone (DX) and erythropoietin (ER)
administration in the CIS- aggravated ototoxicity in rats.
Materials and Methods: Thirty-five rats apportioned into: Control group, CIS group, CIS + DX group received an
intraperitoneal injection of dexamethasone before CIS for 3 consecutive days, CIS + ER group, received an intraperitoneal
injection of ER before CIS for 3 days and CIS + DX + ER group, cisplatin obtained and pretreated with dexamethasone and
erythropoietin. The cochleae were subjected to the histological and immunohistochemical methods.
Results: The DX group exhibited a moderate protective effect against CIS- provoked cellular ototoxicity and remarkably
reduced the histopathological finding. Pretreatment with ER effectually preserved inner and outer hair cells and supporting
cells in the ѻrgan of Cѻrti as compared tѻ the effects distinguished with CIS. Quantification of spiral ganglion neurons by
immunohistological anti-caspase 3 significantly shown that ER-treated rats had a significantly less spiral ganglion neuron
harm than CIS rats. The synergistic dose of DX and ER have better picture nearly near normal histological structure.
Conclusion: These results demonstrated that each DX and ER revolutionize the histological represent of cochlea simply
together were effective and better in protection and treatment of cisplatin- provoked ototoxicity. |
